Department of Cardiothoracic Surgery, Waikato District Health Board, Hamilton, New Zealand.
Waikato Institute of Surgery Education and Research (WISER), Hamilton, New Zealand.
Interact Cardiovasc Thorac Surg. 2021 Jan 1;32(1):106-110. doi: 10.1093/icvts/ivaa215.
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'in patients with ascending aortic or aortic arch disease what are the outcomes with endovascular repair in terms of survival, complications and reintervention?' Altogether 585 papers were found using the reported search, of which 9 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We found that the endovascular operative techniques with the greatest evidence were ascending aortic chimney grafts (AACs), branched thoracic endovascular aortic repair (bTEVAR) aortic grafts and fenestrated TEVAR (fTEVAR) aortic grafts. The best evidence available were small case-series or retrospective cohort studies (n < 100), with 1 systematic review, at a short follow-up period (range 0-5 years). Intraoperatively, these techniques have a high technical success rate (84-100%). We found rates of endoleak comparable between AAC (7.4-16%) and bTEVAR/fenestrated TEVAR (11.1-21.4%). Stroke rates are higher in bTEVAR (3.1-42% vs 1-26% in AACs), attributed to more proximal pathology and technically challenging procedures. Following the immediate postoperative period, the 30-day mortality is 0-10.8% and patency is 97-100%. Stroke and reintervention rates remain higher in the bTEVAR group (3.1-42.0% and 0.5-33.3%) compared to the AAC group (1.0-11.1% and 6.7-16.7%). The 3- and 5-year survival ranges from 59% to 90%, but is driven by non-aortic pathology in a high-risk population; 3-year freedom from aortic death is 93-97%. Patency is 97-100% at up to 3 years, conformation and supra-aortic occlusions thereafter remain unknown. We conclude that AACs, bTEVARs and fenestrated TEVARs are safe endovascular options in high-risk elective patients, with results comparable to open or hybrid repair. They remain unverified in acute settings or in patients fit for open intervention.
一个心脏外科学的最佳证据主题是根据一个结构化的方案撰写的。所提出的问题是:“在患有升主动脉或主动脉弓疾病的患者中,血管内修复在生存率、并发症和再干预方面的结果如何?”总共使用报告的搜索方法找到了 585 篇论文,其中 9 篇论文为回答临床问题提供了最佳证据。作者、期刊、日期和出版国家、研究的患者群体、研究类型、这些论文的相关结果都被制成表格。我们发现,在血管内手术技术方面,最有证据的是升主动脉烟囱移植术(AAC)、分支胸主动脉腔内修复术(bTEVAR)主动脉移植物和开窗 TEVAR(fTEVAR)主动脉移植物。最佳证据是小型病例系列或回顾性队列研究(n<100),有 1 篇系统评价,随访时间短(0-5 年)。在手术过程中,这些技术具有很高的技术成功率(84-100%)。我们发现 AAC(7.4-16%)和 bTEVAR/开窗 TEVAR(11.1-21.4%)之间的内漏率相当。bTEVAR 中的中风发生率较高(3.1-42%比 AACs 中的 1-26%),这归因于更接近近端的病变和技术上具有挑战性的手术。在术后即刻,30 天死亡率为 0-10.8%,通畅率为 97-100%。与 AAC 组(1.0-11.1%和 6.7-16.7%)相比,bTEVAR 组的中风和再干预率仍较高(3.1-42.0%和 0.5-33.3%)。3 年至 5 年的生存率范围为 59%至 90%,但在高危人群中是由非主动脉病变驱动的;3 年无主动脉死亡的生存率为 93-97%。通畅率在 3 年内达到 97-100%,此后的吻合口和超主动脉闭塞情况尚不清楚。我们的结论是,AACs、bTEVARs 和开窗 TEVARs 是高危择期患者安全的血管内选择,结果与开放或杂交修复相当。它们在急性情况下或适合开放干预的患者中尚未得到验证。